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Discordant inflammation and pain in early
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Network and British Society for
Rheumatology Biologics Register data
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Abstract
Background: Rheumatoid arthritis (RA) disease activity is often measured using the 28-joint Disease Activity Score
(DAS28). We aimed to identify and independently verify subgroups of people with RA that may be discordant with
respect to self-reported and objective disease state, with potentially different clinical needs.
Methods: Data were derived from three cohorts: (1) the Early Rheumatoid Arthritis Network (ERAN) and the British
Society for Rheumatology Biologics Register (BSRBR), (2) those commencing tumour necrosis factor (TNF)-α
inhibitors and (3) those using non-biologic drugs. In latent class analysis, we used variables related to pain,
central pain mechanisms or inflammation (pain, vitality, mental health, erythrocyte sedimentation rate, swollen
joint count, tender joint count, visual analogue scale of general health). Clinically relevant outcomes were
examined.
Results: Five, four and four latent classes were found in the ERAN, BSRBR TNF inhibitor and non-biologic
cohorts, respectively. The proportions of people assigned with >80% probability into latent classes were 76%,
58% and 72% in the ERAN, TNF inhibitor and non-biologic cohorts, respectively. The latent classes displayed
either concordance between measures indicative of mild, moderate or severe disease activity; discordantly worse patient-
reported measures despite less markedly elevated inflammation; or discordantly less severe patient-reported measures
despite elevated inflammation. Latent classes with discordantly worse patient-reported measures represented 12%, 40%
and 21% of the ERAN, TNF inhibitor and non-biologic cohorts, respectively; contained more females; and showed worse
function. In those latent classes with worse scores at baseline, DAS28 and function improved over 1 year (p< 0.001 for all
comparisons), and scores differed less at follow-up than at baseline.
Conclusions: Discordant latent classes can be identified in people with RA, and these findings are robust across three
cohorts with varying disease duration and activity. These findings could be used to identify a sizeable subgroup of people
with RA who might gain added benefit from pain management strategies.
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Background
Rheumatoid arthritis (RA) is an inflammatory arthritis in
which chronic pain is prevalent. Inflammatory disease
activity in RA is often measured using the composite
28-joint Disease Activity Score (DAS28), consisting of
28-joint swollen joint count (SJC), 28-joint tender joint
count (TJC), erythrocyte sedimentation rate (ESR) and
visual analogue scale (VAS) for general health (VAS-
GH). These components are either patient-reported
(TJC, VAS), clinician-assessed (SJC) or laboratory-
measured. Patient-reported components reflect symp-
tomatic disease, whilst other components more directly
address inflammatory pathology. The discrete DAS28
components are each correlated with one another, sup-
porting the view that DAS28 measures a single entity
(RA inflammatory disease activity) [1]. However, the two
patient-reported components (TJC and VAS-GH) are
also strongly influenced by reported pain, which might
be moderated by factors additional to inflammation,
such as the processing of afferent signals by the central
nervous system [2–4]. Indeed, there is now considerable
evidence that psychological factors such as anxiety and
vitality influence not only inflammatory and immune
responses but also perception of pain [5].
TJC, VAS and the proportion of DAS28 attributable to
patient-reported measures were each associated with
reported pain [6, 7], and they predicted future pain in
people with RA [3, 8]. Patient-reported DAS28 compo-
nents in RA were also associated with widespread low
pain pressure thresholds (suggesting augmented central
pain processing), poorer mental health, fatigue and fibro-
myalgia status, independent of inflammatory disease ac-
tivity [6–9]. Pain, fatigue and mental health are closely
inter-related constructs because of their overlapping
symptoms and shared central neurological mechanisms
[8, 10–12] as well as psychological traits such as anxiety
[5]. Each is recognised in people without RA who are di-
agnosed with fibromyalgia [12], and people with fibro-
myalgia might display DAS28 scores similar to those of
people with active RA, predominantly owing to high TJC
and VAS, and despite an absence of any joint inflamma-
tion [13]. One-fifth of people with RA also satisfied clas-
sification criteria for fibromyalgia, and they display
multiple tender points at non-joint sites, widespread
pain, mood disturbance and fatigue [10–12]. In these
cases, augmented pain processing might contribute to
pain severity, thereby worsening patient-reported DAS28
components and total DAS28 without concordant in-
flammation and without necessarily leading to joint
damage [14, 15].
People with discordantly high patient-reported DAS28
components, fatigue and mood disturbance might repre-
sent a subgroup of people with RA who have unique
clinical needs. Defining patient subgroups, being person-
based rather than variable-based, can help target treat-
ments towards those people who are most likely to
benefit [5]. Treatments of some tumours are already
stratified according to molecular profiles [16], and re-
search is underway to stratify RA therapies on the basis
of inflammatory mechanisms [17, 18]. Identifying patient
subgroups in which outcomes are determined by factors
other than inflammation might improve allocation of
both immunomodulatory therapies and adjunctive pain
management strategies [5].
Hierarchical clustering analysis previously defined a
subgroup of individuals with established RA that was
characterised by low levels of inflammation but high
levels of symptoms [19]. Discrete subgroups within pop-
ulations can also be identified by latent class analysis
(LCA), a branch of structural equation modelling [20].
LCA has advantages over hierarchical clustering analysis
in that the optimal number of classes is decided using
clear fit statistics, and people are assigned to classes
using probabilistic routines, allowing hypothesis testing
for different models and reducing the amount of subject-
ivity in model choice [19]. Each person has a probability
of membership in each subgroup, as opposed to an abso-
lute assignment given by other methodologies. Previous
studies of RA using LCA-related techniques include
longitudinal trajectories of physical function [21] and
genome analysis [22].
We hypothesised that simple-to-measure validated in-
struments and clinical examination measuring the
current characteristics of pain and inflammation can be
used to define discrete subgroups of people with RA for
whom patient-reported symptoms are concordant, and
other subgroups for whom patient-reported symptoms
are discordantly worse than might be expected based on
clinician-assessed or laboratory measures of inflamma-
tion. Concordant and discordant subgroups might have
differing prognoses in the context of current care. We
have undertaken hypothesis-driven LCA, cross-validated
across three large samples: the Early Rheumatoid
Arthritis Network (ERAN) cohort and two established
RA cohorts from the British Society for Rheumatology
Biologics Registers (BSRBR) either commencing tumour
necrosis factor (TNF)-α inhibitors or using only non-
biologic disease-modifying drugs [23]. Together these
data reflect people with early or established RA and
those treated with traditional or biologic disease-
modifying anti-rheumatic drugs (DMARDs).
Methods
ERAN was an inception cohort of people with early RA,
all recruited at the time of first physician’s diagnosis of
RA, with data collection from 2002 until 2014 [24]. Data
were excluded if diagnosis changed at a later date (n = 36).
The BSRBR cohorts recruited people with RA of any
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duration, and data are included in the present study where
participants commenced either etanercept or adalimumab
(TNF inhibitor cohort) or had physician-assessed active
RA but were not commencing a biologic agent (non-bio-
logic cohort) [25]. Most non-biologic cohort participants
were commencing or changing non-biologic DMARD
treatment [26] at baseline and therefore were thought by
their clinicians to have active disease. (Baseline character-
istics are summarised in Table 1.) Registration and enrol-
ment in the BSRBR of new users of biologics was
recommended by national guidelines at the time of
recruitment. Data collection for BSRBR cohorts com-
menced in 2001, as described elsewhere [27]. For all three
cohorts, data were collected using standardised question-
naires (Health Assessment Questionnaire [HAQ] and 36-
item Short Form Health Survey [SF-36]), clinical examin-
ation, medical records and clinical report forms by the
clinical team responsible for the patient’s care. DAS28
components (TJC, SJC, acute-phase response as measured
by ESR, and VAS) were assessed at baseline, at 3–6
months (ERAN) or 6 months (BSRBR cohorts), and at 12-
month follow-up visits. Mean DAS28, pain, disability and
vitality outcomes for one or both of the cohorts during
early follow-up have previously been reported for the
ERAN [3, 28–30] and BSRBR [9, 31, 32] cohorts. All par-
ticipants gave signed, informed consent to participate in
line with the Declaration of Helsinki. The ERAN study
was approved by Trent Research Ethics Committee
(reference 01/4/047). The BSRBR studies were approved
by North West Medical Research Ethics Committee
(reference 00/8/53).
Selection of variables
Variables were selected for LCA on the basis of our a
priori hypothesis if they measured factors believed to
reflect current inflammation, pain experience or central
pain processing. Three SF-36 subscales relevant to our
hypothesis were included. Bodily pain is a direct meas-
ure of pain symptoms and functional limitation attrib-
uted to pain [33]. Vitality is a measure of fatigue, and
SF-36 mental health component scores use items ad-
dressing low mood and anxiety. Additional variables
were used to compare baseline demographic and clinical
characteristics between latent classes (age, sex, current
smoking status, symptom/disease duration, body mass
index, serology, SF-36 mental and physical component
scores, or DAS28). Clinically relevant outcome variables
(DAS28, SF-36 physical function score and HAQ) [34]
were also retrieved from baseline to 1-year follow-up.
Statistical analysis
LCAs were performed on baseline data. Variables were
standardised prior to LCA using their theoretical max-
imum so that each had a range of 0–1 and had higher
values indicating greater severity. SF-36 subscales were
transformed using the formula (100 − SF-36)/100, which
yielded standardised scores of increasing severity, and
ESR values were log-transformed. List-wise exclusion of
missing data (complete case analysis) was employed as
our primary analysis strategy. Missingness was highest
Table 1 Demographics and baseline variables
ERAN BSRBR
TNF inhibitor Non-biologic
Total subjects 828 9905 2581
Age, years 57 (14) 56 (12) 60 (12)
Female sex 67% 76% 73%
BMI, kg/m2 27.6 (5.3) 27.0 (7.3) 27.4 (6.7)
Smoking status
Never 39% 40% 38%
Ex-smoker 25% 38% 41%
Current 36% 22% 21%
Duration, years 0.7 (0.6) 13 (10) 10 (10)
Positive serology 60% 65% 57%
1987 ACR criteria, yes 53% 100% 100%
DAS28-ESR 4.7 (1.5) 6.6 (1.0) 5.1 (1.3)
ESR, mm/h 30 (24) 46 (29) 34 (24)
SJC, 0–28 6 (5) 11 (6) 6 (5)
TJC, 0–28 7 (7) 16 (7) 8 (7)
VAS, 0–100 44 (25) 72 (20) 54 (24)
HAQ, 0–3 1.1 (0.8) 2.0 (0.6) 1.5 (0.8)
SF-36
Physical function 30 (15) 16 (11) 24 (11)
Bodily pain 33 (11) 25 (7) 31 (9)
Vitality 42 (11) 33 (10) 39 (10)
Mental health 46 (11) 40 (11) 45 (11)
PCS 29 (12) 16 (8) 24 (11)
MCS 47 (12) 44 (11) 48 (11)
DMARD by 6-month follow-up 91% 100% 100%
First recorded DMARD
MTX monotherapy 48% 40% 0%
SSZ monotherapy 31% 14% 0%
MTX combination 12% 25% 0%
Biologic 0% 0% 100%
Baseline variables of the complete cases for the cohorts. Mean (SD) or
percentage data are presented
Abbreviations: ACR American College of Rheumatology, BSRBR British Society
for Rheumatology Biologics Registers, DAS28 28-joint Disease Activity Score,
DMARD Disease-modifying anti-rheumatic drug, ERAN Early Rheumatoid
Arthritis Network, ESR Erythrocyte sedimentation rate, HAQ Health Assessment
Questionnaire, SF-36 36-item Short Form Health Survey, SJC Swollen joint
count, TJC Tender joint count, TNF Tumour necrosis factor, VAS Visual analogue
scale, PCS Short Form Health Survey physical component score, MCS Short
Form Health Survey mental component score, MTX methotrexate,
SSZ sulphasalazine
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for SF-36 variables and ESR, which were between 10%
and 20%, and other variables were all below 5%.
The selection of the optimum number of classes was
guided by iteratively comparing several diagnostic indi-
ces [35, 36] from k categories to those from the k − 1
categories. Lower values of the Bayesian information
criterion, the Akaike information criterion and a non-
significant Vuong-Lo-Mendell-Rubin (VLMR) adjusted
likelihood ratio test, as well as the bootstrap likelihood
ratio test (BLRT), all suggested better fit. Higher values
of the entropy implied higher probabilities of people be-
ing assigned to the correct latent class. The VLMR and
the BLRT both had associated significance tests for guid-
ance purposes, whereas the other measures were
assessed by comparison with their scores with k − 1 cat-
egories. Models where latent classes showed member-
ship of <5% of the total cohort size were rejected. Thus,
the final determination of classes was based on theoret-
ical and clinical significance in conjunction with the fit
indicators [37].
Descriptive names for different classes were selected
to reflect our hypothesis by comparing the discordance
or concordance of values of patient-reported measures
with clinician- or laboratory-assessed measures. Clinical
judgement and the relative values of each score (both
within and across cohorts) were taken into account.
These were selected after the LCA had been completed
and the mean values of each class were known. Charac-
teristics of participants allocated to each class were com-
pared using one-way analysis of variance (ANOVA) and
then using pairwise t tests with Bonferroni corrections.
LCA was performed using Mplus version 7.2 software
(Muthén and Muthén, Los Angeles, CA, USA). Data
management and analyses other than LCA were per-
formed using IBM SPSS version 22 software (IBM,
Armonk, NY, USA). Statistical significance was taken as
p < 0.05.
DAS28, HAQ and SF-36 physical function outcomes
during the first year of follow-up were assessed graphic-
ally and using descriptive statistics for change values for
each latent class, and by comparing 12-month follow-up
data between latent classes using multivariate ANOVA.
Only participants with complete data at three time
points (baseline, 3–6 months, and 12-month follow-up)
were included, and the demographics and clinical char-
acteristics of this subgroup were compared with those
included in baseline analyses to ensure appropriate
representation.
Results
Baseline demographics and clinical details of participants
included for LCA in each cohort are presented in
Table 1. ERAN participants had shorter symptom dur-
ation (median 0.5 years) than BSRBR participants
(median ≥6 years) and were less likely than BSRBR par-
ticipants to satisfy 1987 American College of Rheuma-
tology criteria for RA (53% vs. 100%, respectively).
BSRBR TNF inhibitor participants had higher DAS28
scores, worse HAQ disability and worse quality-of-life
measures than did ERAN and BSRBR non-biologic
participants.
Comparable latent classes were identified in each of
the three cohorts. The process of selecting LCA models
for each cohort is summarised through the indices listed
in Table 2. When all of the different diagnostic indices
were taken into account, the final decision regarding the
number of classes was taken in reference to two main
factors: the size of the latent classes and VLMR p values
reaching cut-off criteria. Further selection of additional
latent classes would be likely to be less robust. The com-
position of each latent class is summarised in Table 3,
showing the population percentage, the mean scores for
each variable, and the percentage of cases that the model
classified with higher levels of likelihood (80% or 95%
probabilities). Five latent classes were selected in the
ERAN cohort, and four were selected in the BSRBR co-
horts (Fig. 1). Latent classes that had been selected were
named on the basis of clinical interpretation of group
characteristics, severity (mild, moderate, severe) and
concordance of patient-reported with clinician-observed
and laboratory-measured variables.
In each cohort, at least two latent classes displayed
concordance between patient-reported, clinician-
observed and laboratory-measured indices. These latent
classes were distinguished by severity in each scale. Each
cohort also included one discordant latent class with
worse patient-reported indices, but relatively low
clinician-observed and laboratory-measured indices. Fur-
thermore, each cohort also included one latent class with
discordantly low patient-reported indices, despite relatively
high clinician-observed or laboratory-measured indices.
In the ERAN cohort, three concordant classes ap-
peared to reflect, respectively, subgroups with mild (26%
of participants), moderate (38%) or severe RA (10%)
(Table 3, Fig. 1). The discordant latent class in ERAN
with worse patient-reported indices (12%) showed the
worst mean bodily pain, VAS-GH, vitality and mental
health scores alongside laboratory-measured and
physician-observed indices that were comparable (ESR)
or better (SJC) in the concordant severe latent class. The
discordant latent class in ERAN with better patient-
reported indices (11%) showed high levels of the
laboratory-measured and physician-observed indices
(ESR, SJC), which were comparable to the concordant,
severe latent class, alongside better scores for patient-
reported indices (comparable to the moderate or mild,
concordant latent classes). Concordant moderate and
mild or severe latent classes, and discordant with worse
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or better patient-reported indices, were identified in the
BSRBR cohorts that were comparable to those identified
in ERAN. Discordant latent classes with relatively worse
patient-reported measures comprised 12%, 40% and 21%
of ERAN, BSRBR TNF inhibitor and non-biologic partic-
ipants, respectively (Table 3), and displayed age, sex,
DAS28 and HAQ scores similar to the concordant
severe classes (Table 4). Comparison of additional base-
line characteristics between latent classes is given in
Additional file 1: Table S1.
Mean DAS28 and functional status scores changed at
different rates during 12 months of follow-up (p < 0.001
for all comparisons) (Fig. 2a–c) and improved most in
those latent classes with the worst baseline scores
(Fig. 2). Baseline scores explained changes in HAQ
across 12 months because the multivariate test of differ-
ent latent classes lost significance after adjustment for
baseline HAQ in each cohort (p = 0.374, p = 0.772 and p =
0.238 for ERAN, BSRBR biologic and non-biologic cohorts,
respectively). The changes in DAS28 across 12 months
were not completely explained by baseline DAS28, because
the significance of the multivariate test for the different
latent classes was retained (p = 0.026, p < 0.001 and p <
0.0.001, respectively), and changes in SF-36 physical func-
tion were explained only by baseline scores in one cohort
(p = 0.080, p < 0.001 and p < 0.001, respectively).
Discussion
We have shown that people with RA can be allocated to
four or five discrete latent classes that reflect either dif-
fering degrees of inflammatory disease activity or dis-
cordance between patient-reported and clinician- or
laboratory-measured indices of inflammation. Our ana-
lyses show subgroups of patients with RA for whom
DAS28 might either underestimate (discordant, worse
patient-reported indices in 12–40% of participants) or
overestimate (discordant, better patient-reported indices
in 10–23%) their need for DMARD escalation or for
whom additional strategies might be used to augment
clinical benefit from biologic or non-biologic DMARDs.
DAS28 is widely used to direct RA treatment with bio-
logic or non-biologic treatments. Some countries restrict
access to biologic therapy to those patients who have a
persistent DAS28 above a threshold level [38], and treat-
Table 2 Summary of selection process for latent class analysis models
Classes in model AIC BIC SS-BIC Entropy VLMR BLRT Percentage in each class (in order of size)
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6
ERAN cohort
1 −5458 −5392 −5738 Not available 100%
2 −5858 −5753 −5823 0.78 2387* 2387* 56% 44%
3 −6229 −6087 −6182 0.81 2951* 2951* 52% 33% 15%
4 −6395 −6214 −6335 0.80 3145** 3145* 48% 27% 13% 12%
5 −6552 −6333 −6480 0.80 3235*** 3235* 40% 26% 13% 11% 10%
6 −6645 −6389 −6560 0.82 3311 3311* 40% 26% 11% 11% 10% 2%
British Society for Rheumatology Biologics Registers TNF inhibitor cohort
1 −69,795 −69,695 −69,739 Not available 100%
2 −77,781 −77,623 −77,693 0.65 36,175* 36,175* 62% 38%
3 −79,445 −79,229 −79,325 0.71 38,913** 38,913* 53% 41% 6%
4 −80,851 −80,578 −80,698 0.69 39,753* 39,753* 40% 23% 21% 16%
5 −81,896 −81,565 −81,711 0.70 40,464* 40,464* 32% 24% 22% 19% 2%
British Society for Rheumatology Biologics Registers non-biologic cohort
1 −19,209 −19,127 −19,172 Not available 100%
2 −21,497 −21,368 −21,438 0.70 9618* 9618* 56% 44%
3 −22,638 −22,462 −22,557 0.76 10,770* 10,770* 51% 34% 15%
4 −23,170 −22,947 −23,068 0.76 11,349* 11,349* 51% 21% 18% 10%
5 −23,457 −23,188 −23,334 0.76 11,623 11,623* 45% 20% 19% 11% 5%
Selection diagnostics for latent class analysis are summarised for models with different numbers of classes. Each model was compared with the previous model
with one fewer latent classes. The percentage assigned to each latent class is shown. The model that was selected as the optimal fit is highlighted in bold
Abbreviations: AIC Akaike information criterion, BIC Bayesian information criterion, BLRT Bootstrap likelihood ratio test, ERAN Early Rheumatoid Arthritis Network,
TNF Tumour necrosis factor, VLMR Vuong-Lo-Mendell-Rubin likelihood ratio test, SS-BIC Sample size-adjusted Bayesian information criterion
*p < 0.001
**p < 0.01
***p < 0.05 (significance tests are applied for VLMR and BLRT only)
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Table 3 Composition of each latent class
ERAN BSRBR TNF inhibitor cohort BSRBR non-biologic cohort
Concordant/discordant Con Con Con Dis Dis Con Con Dis Dis Con Con Dis Dis
Descriptor Mild Moderate Severe Better patient-
reported
Worse patient-
reported
Moderate Severe Better patient-
reported
Worse patient-
reported
Mild Moderate Better patient-
reported
Worse patient-
reported
Number of subjects 220 329 86 91 102 1544 2117 2289 3955 476 1308 248 549
Percentage of total 26% 38% 10% 11% 12% 16% 21% 23% 40% 18% 51% 10% 21%
ESR 22 (19) 25 (18) 42 (29) 40 (26) 44 (29) 42 (27) 52 (31) 39 (26) 49 (29) 27 (21) 33 (23) 44 (28) 38 (26)
SJC 3 (3) 4 (3) 12 (6) 14 (5) 7 (4) 9 (5) 15 (6) 14 (6) 9 (5) 4 (4) 5 (3) 16 (5) 6 (4)
TJC 2 (3) 5 (4) 22 (4) 11 (5) 9 (5) 9 (4) 23 (4) 21 (4) 11 (4) 4 (4) 7 (5) 20 (6) 11 (6)
VAS 20 (15) 44 (20) 66 (20) 50 (20) 73 (16) 57 (20) 84 (15) 69 (19) 74 (18) 34 (21) 51 (21) 72 (18) 69 (16)
BP 46 (6) 31 (7) 24 (6) 32 (6) 22 (5) 34 (7) 20 (4) 27 (6) 23 (5) 43 (6) 31 (5) 27 (7) 23 (5)
VT 52 (9) 40 (8) 33 (8) 46 (8) 30 (8) 45 (9) 25 (6) 39 (9) 30 (7) 51 (7) 39 (7) 36 (9) 28 (6)
MH 55 (7) 45 (9) 39 (9) 52 (8) 32 (10) 50 (9) 32 (10) 46 (9) 38 (10) 56 (7) 47 (9) 43 (10) 32 (9)
Probability of membership of latent class
> 80% probability 89% 73% 78% 57% 70% 66% 65% 53% 66% 74% 74% 77% 63%
> 95% probability 71% 40% 56% 30% 41% 40% 37% 22% 38% 51% 36% 59% 38%
Baseline variables used in latent class analysis are summarised to describe composition of each latent class identified within each cohort. The number of participants and the mean (SD) of each variable are shown. The
percentage of cases allocated to each latent class is shown for those with a probability of membership in that class >80% or >95%
Abbreviations: BSRBR British Society for Rheumatology Biologics Registers, Dis Discordant, Con Concordant, ESR Erythrocyte sedimentation rate, SJC Swollen joint count, TJC Tender joint count, VAS Visual analogue scale
for general health, BP Short Form Health Survey bodily pain, VT Short Form Health Survey vitality, MH Short Form Health Survey mental health, TNF Tumour necrosis factor
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to-target approaches are increasingly recommended
whereby DAS28 informs DMARD treatment escalation
[17]. We have consistently identified discordant sub-
groups within all three studied cohorts, suggesting gen-
eralisability through both early and established RA and
in patients with apparently active disease being consid-
ered for either biologic or non-biologic DMARDs.
Discordant subgroups represented 23–63% of participants
in each studied cohort, suggesting that non-inflammatory
factors have a major influence on interpretation of DAS28
as a measure of inflammatory disease activity.
Central mechanisms might augment pain in people
with RA, and this discordance between DAS28 compo-
nents might reflect the balance between peripherally
and centrally acting pain mechanisms [3, 7–9, 38].
Our data are therefore consistent with previous findings
that pain moderates inflammatory disease assessment
[5, 7, 11, 14] and that DAS28 might overestimate inflam-
matory disease activity, particularly in the context of
augmented central pain processing [32].
In addition, we identified discrete subgroups of pa-
tients for whom patient-reported measures were better
than might be expected from clinician- and laboratory-
measured DAS28 components. The ‘typus robustus’ RA
phenotype [39] might represent one extreme of this dis-
cordant subgroup. It is increasingly recognised that pa-
tients with moderate disease activity based on DAS28
have poor outcomes, and this might particularly be the
case for those in whom total DAS28 is suppressed by
discordantly low patient-reported components. This
might reflect a hidden need for escalating biologic or
non-biologic DMARD therapy. However, further re-
search is needed to determine whether DMARD escal-
ation in this patient subgroup would have greater
benefits for retarding joint damage and chronic disability
than in people with similar DAS28 who are concordant or
who show discordantly high patient-reported measures.
Our data support previous observations that people
with more severe disease at baseline, measured either by
patient self-report or by clinician or laboratory assessment,
Fig. 1 Latent classes of baseline inflammation and pain-related variables. Left y-axis = variables standardised from 0 to 1 to allow comparison
between different indices. Increasing severity is reflected by increasing scores. Right y-axis = reference points for normal or low activity
scores for different variables. BP Short Form Health Survey bodily pain score, BSRBR British Society for Rheumatology Biologics Registers,
ERAN Early Rheumatoid Arthritis Network, VT Short Form Health Survey vitality score, MH Short Form Health Survey mental health score,
ESR Erythrocyte sedimentation rate, SF-36 36-item Short Form Health Survey, SJC Swollen joint count, TJC Tender joint count, TNF Tumour
necrosis factor VAS Visual analogue scale. Names of classes are descriptive
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Table 4 Baseline characteristics of the latent classes
ERAN BSRBR TNF inhibitor cohort BSRBR control cohort
Concordant/
Discordant
Con Con Con Dis Dis Heterogeneity Con Con Dis Dis Heterogeneity Con Con Dis Dis Heterogeneity
Descriptor Mild Moderate Severe Better
patient-
reported
Worse
patient-
reported
Moderate Severe Better
patient-
reported
Worse
patient-
reported
Mild Moderate Better
patient-
reported
Worse
patient-
reported
Age 58 (13) 56 (14) 55 (14) 58 (13) 57 (13) 56 (13) 56 (12) 57 (14) 56 (12) * 60 (12) 61 912) 59 (12) 59 (12) *
Female 60% 68% 65% 66% 81% * 72% 79% 75% 77% * 69% 73% 71% 77% *
DAS28 3.2 (1.1) 4.3 (1.0) 6.9 (0.8) 6.0 (0.7) 5.7 (0.8) * 5.6 (0.9) 7.5 (0.7) 7.0 (0.7) 6.2 (0.7) * 4.1 (1.1) 4.9 (1.0) 7.0 (0.8) 5.7 (1.0) *
HAQ 0.4 (0.5) 1.1 (0.6) 1.8 (0.6) 1.3 (0.6) 1.8 (0.7) * 2.0 (0.6) 2.0 (0.6) 2.1 (0.6) 2.0 (0.6) 0.7 (0.6) 1.5 (0.6) 1.8 (0.6) 2.1 (0.5) *
Clinical variables not used in the latent class analysis are compared between identified latent classes. Mean (SD) or percentage data are presented
Abbreviations: BSRBR, British Society for Rheumatology Biologics Registers, DAS28 28-joint Disease Activity Score, ERAN Early Rheumatoid Arthritis Network, HAQ Health Assessment Questionnaire, TNF Tumour necrosis
factor, Dis Discordant, Con Concordant
*p < 0.05 from one-way analysis of variance for heterogeneity between latent classes within one cohort
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appear to have the greatest scope for improvements, and la-
tent classes with worse baseline scores displayed greater im-
provements during follow-up. Improvement in those with
worse baseline scores might partially be attributable to re-
gression to the mean, but might also be expected after
commencing new treatments. Further research is required
to determine whether patients with discordantly high
patient-reported indices might gain particular benefit from
adjunctive treatments targeting pain management and
psychological distress. Despite the prospective nature
of our study cohorts, we are unable to distinguish be-
tween sustained disease activity and shorter-term flares.
Further research might investigate whether latent classes
defined by inflammation and patient-reported variables
can predict inflammatory or symptomatic flares in people
with RA.
DMARDs improve patient-reported indices by sup-
pressing inflammation and through placebo effects [40],
which might be particularly pronounced for expensive
treatments with limited availability, such as biologic
agents. Furthermore, inflammation might drive changes
in central neuronal processes, leading to augmented
pain, fatigue and mood disturbance [41]. These multiple
peripheral and central modes of action might conceal
treatment response differences between latent classes,
despite differing underlying disease mechanisms. We did
not identify differences in responses to biologic or non-
biologic DMARDs between discordant patient subgroups.
Fig. 2 Early longitudinal changes in the three cohorts. Changes in mean clinical and functional scores over the first year from recruitment
for 28-joint Disease Activity Score (DAS28) (a, b, c), Health Assessment Questionnaire (HAQ) (d, e, f) and 36-item Short Form Health
Survey (SF-36) physical function (g, h, i), stratified by latent class subgroup. Cohorts displayed are the Early Rheumatoid Arthritis Network
(ERAN) (a, d, g), British Society for Rheumatology Biologics Registers (BSRBR) tumour necrosis factor (TNF) inhibitor (b, e, h) and BSRBR
non-biologic (c, f, i). BL Baseline, 6 m 6 months, 1y 1 year. Complete cases were analysed, yielding respective sample sizes for ERAN, BSRBR
TNF inhibitor and BSRBR non-biologic for DAS28 (n = 383, 6376 and 887, respectively), HAQ (n = 447, 5627 and 1601, respectively) and SF-36 physical
function (n = 217, 6179 and 1706, respectively). There was significant heterogeneity between the changes in scores of all of the latent classes for each
cohort and for each measure (p < 0.001 for each comparison)
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Nonetheless, our data indicate that patient subgroups can
be identified prior to treatment changes on the basis
of existing, easily administered clinical assessment
and questionnaires. Entropy measurements in the
0.7–0.8 range for all models tested in the present
study indicate good levels of confidence in our sub-
grouping of individuals.
Patient-reported variables might be particularly useful
for stratifying treatment modalities used as adjuncts to
DMARD therapies. However, using widespread pain
alone for selective recruitment of participants was not
adequate in a clinical trial of the centrally acting anal-
gesic milnacipran in people with RA, although the num-
ber of participants might be small and secondary
analysis implicated a confounding effect of synovitis on
the pain measurements [42]. Clustering algorithms based
on studies such as ours and others [19] represent an
alternative tool for determining recruitment criteria for
personalised medicine trials.
There are some limits to the generalisability of our
findings. The characteristics of each cohort will have in-
fluenced the latent classes that were identified. For ex-
ample, a ‘concordant, mild’ subgroup was not identified
in the BSRBR TNF inhibitor cohort, probably because
patients were recruited to this cohort following selection
for TNF inhibitor treatment based on the presence of
active inflammatory disease. DAS28 scores were mea-
sured by different assessors across different centres, and
variability in scores between cohorts and between study
centres might have introduced bias, as well as lowering
precision. It is possible that the non-independent assess-
ments of SJC and TJC (assessed during a single clinical
examination) might also have introduced bias and re-
duced apparent discordance between these patient-
reported and clinician-assessed components. Patients in
the BSRBR non-biologic cohort were also recruited with
clinician-assessed active disease, and patients were re-
cruited to ERAN shortly after first presentation to sec-
ondary care, usually before DMARD therapy had been
optimised. Subgroups with RA and mild inflammatory
disease activity or discordantly low DAS28 components
might therefore be under-represented in our cohorts
compared with a more general RA population. Further-
more, most participants in our study changed DMARD
therapy after baseline assessment, and different latent
classes might be found in people with RA undergoing
stable treatment. However, the consistency of our find-
ings across different RA populations, as well as evidence
of central sensitisation or from classification of fibro-
myalgia in established stable RA [7, 8, 10], suggests
that our findings might be generally applicable. The
relationship between latent classes identified in this study
and underlying disease mechanisms requires further
elucidation, and more direct measures of central pain
mechanisms (e.g., quantitative sensory testing or func-
tional magnetic resonance imaging) might better distin-
guish between patient subgroups.
Conclusions
We demonstrate latent classes amongst patients with
early or established RA based on patient-reported and
clinician- or laboratory-measured indices of inflamma-
tion and pain. Discordant classes representing patients
with worse or better patient-reported measures than
might be suggested by clinician- or laboratory-measured
inflammation contribute a high proportion of people
with high DAS28. Randomised controlled trials are
needed to determine whether patient subgrouping or
stratification based on patient-reported and clinician- or
laboratory-measured indices can improve effectiveness
or cost-effectiveness of RA management or reduce un-
necessary exposure of patients to DMARD and biologic
escalation strategies when interventions targeting pain
processing might be more suitable.
Additional file
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